Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 11/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26539353 | 0.90 | SCN5A (0.49) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20203952 | 0.86 | SCN5A (0.62) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20191029 | 0.85 | SCN5A (0.61) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20190617 | 0.85 | SCN5A (0.61) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20191087 | 0.81 | SCN5A (0.57) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20203983 | 0.81 | SCN5A (0.57) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20190576 | 0.81 | SCN5A (0.56) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20203969 | 0.80 | CYP1A2 (0.58) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20204073 | 0.80 | SCN5A (0.55) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 | |
| SCHEMBL20203975 | 0.77 | SCN5A (0.52) | SCN5ACYP1A2SCN1ASCN2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4397308-A2 | COMPOUNDS AND THEIR METHODS OFUSE | Praxis Precision Medicines, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3548033-B1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3548033-A1 | COMPOUNDS AND THEIR METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11629146-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as modulators of sodium channel activity | SCN1A, SCN5A, SCN3A | SCN5A 2/4885CYP1A2 2190/4885SCN1A 1/4885 |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885SCN1A 1/4885 |
| US-20250163068-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885SCN1A 1/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | SCN5A 8/4885CYP1A2 1988/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.